Evidence map›Paper›PMID 37726928›Full record

ArticleESC heart failure2023

Detection of transthyretin amyloid cardiomyopathy by automated data extraction from electronic health records.

Ana Moya, Clara L Oeste, Monika Beles, Sofie Verstreken, Riet Dierckx, Ward Heggermont, Jozef Bartunek, Eline Bogaerts, Imke Masuy, Dries Hens and 2 more

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 3 countries.

Ana MoyaCardiovascular Center, OLV Hospital Aalst, Moorselbaan n. 164, Aalst, 9300, Belgium.
Clara L OesteLynxCare Inc., Leuven, Belgium.ORCID 0000-0002-7035-132X
Monika BelesCardiovascular Center, OLV Hospital Aalst, Moorselbaan n. 164, Aalst, 9300, Belgium.
Sofie VerstrekenCardiovascular Center, OLV Hospital Aalst, Moorselbaan n. 164, Aalst, 9300, Belgium.
Riet DierckxCardiovascular Center, OLV Hospital Aalst, Moorselbaan n. 164, Aalst, 9300, Belgium.
Ward HeggermontCardiovascular Center, OLV Hospital Aalst, Moorselbaan n. 164, Aalst, 9300, Belgium.
Jozef BartunekCardiovascular Center, OLV Hospital Aalst, Moorselbaan n. 164, Aalst, 9300, Belgium.
Eline BogaertsCardiovascular Center, OLV Hospital Aalst, Moorselbaan n. 164, Aalst, 9300, Belgium.
Imke MasuyLynxCare Inc., Leuven, Belgium.
Dries HensLynxCare Inc., Leuven, Belgium.
Dario BertoloneCardiovascular Center, OLV Hospital Aalst, Moorselbaan n. 164, Aalst, 9300, Belgium.
Marc VanderheydenCardiovascular Center, OLV Hospital Aalst, Moorselbaan n. 164, Aalst, 9300, Belgium.
Onze Lieve Vrouwziekenhuis Hospital · BEMemorialCare Health System · US

Funding

Cardiovascular Center, OLV Hospital AalstLynxCare Clinical Informatics
6 · The paper itself

Abstract

aimsTransthyretin amyloid cardiomyopathy (ATTR-CM), a progressive and fatal cardiomyopathy, is frequently misdiagnosed or entails diagnostic delays, hindering patients from timely treatment. This study aimed to generate a systematic framework based on data from electronic health records (EHRs) to assess patients with ATTR-CM in a real-world population of heart failure (HF) patients. Predictive factors or combinations of predictive factors related to ATTR-CM in a European population were also assessed. METHODS AND

resultsRetrospective unstructured and semi-structured data from EHRs of patients from OLV Hospital Aalst, Belgium (2012-20), were processed using natural language processing (NLP) to generate an Observational Medical Outcomes Partnership Common Data Model database. NLP model performance was assessed on a random subset of EHRs by comparing algorithm outputs to a physician-generated standard (using precision, recall, and their harmonic mean, or F1-score). Of the 3127 HF patients, 103 potentially had ATTR-CM (age 78 ± 9 years; male 55%; ejection fraction of 48% ± 16). The mean diagnostic delay between HF and ATTR-CM diagnosis was 1.8 years. Besides HF and cardiomyopathy-related phenotypes, the strongest cardiac predictor was atrial fibrillation (AF; 72% in ATTR-CM vs. 60% in non-ATTR-CM, P = 0.02), whereas the strongest non-cardiac predictor was carpal tunnel syndrome (21% in ATTR-CM vs. 3% in non-ATTR-CM, P < 0.001). The strongest combination predictor was AF, joint disorders, and HF with preserved ejection fraction (29% in ATTR-CM vs. 18% in non-ATTR-CM: odds ratio = 2.03, 95% confidence interval = 1.28-3.22).

conclusionsNot only well-known variables associated with ATTR-CM but also unique combinations of cardiac and non-cardiac phenotypes are able to predict ATTR-CM in a real-world HF population, aiding in early identification of ATTR-CM patients.

Indexed as

Amyloid Neuropathies, FamilialCardiomyopathiesHeart FailureAgedAged, 80 and overDelayed DiagnosisElectronic Health RecordsFemaleHumansMalePrealbuminRetrospective StudiesPrealbuminDiagnosisHeart failurePhenotypeTransthyretin amyloid cardiomyopathy

Identifiers

PMID37726928
PMCPMC10682883
OpenAlexW4386877913

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.